BIOBIJOU Co., Ltd. Logo

BIOBIJOU Co., Ltd.

Develops and manufactures injectable aesthetic solutions like HA fillers for global markets.

489460 | KO

Overview

Corporate Details

ISIN(s):
KR7489460006
LEI:
Country:
South Korea
Address:
경기도 하남시 하남대로 947 에이동 1516호, 하남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BIOBIJOU Co., Ltd. is a global medical aesthetics company established in 2018. It specializes in the research, development, manufacturing, and sale of injectable products such as skin boosters, hyaluronic acid (HA) fillers, and fat-dissolving solutions, alongside other cosmetic items. The company manages an integrated value chain, from R&D and product design to production in its own GMP-certified facilities and global distribution. BIOBIJOU has established a robust sales network, exporting to over ten countries with a strong presence in the Chinese market. Through strategic R&D alliances and investment in high-level manufacturing, the company aims to deliver high-quality, competitively priced aesthetic solutions to the global market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-05-20 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 89.4 KB
2025-05-20 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.8 KB
2025-05-20 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.9 KB
2025-05-13 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 211.9 KB
2025-05-02 00:00
Registration Form
[발행조건확정]증권신고서(지분증권)
Korean 495.1 KB
2025-05-02 00:00
Prospectus
[기재정정]투자설명서
Korean 3.6 MB
2025-04-29 00:00
Prospectus
투자설명서
Korean 3.1 MB
2025-04-18 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 3.1 MB
2025-04-07 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 4.0 MB
2025-03-24 00:00
Annual / Quarterly Financial Statement
[기재정정]감사보고서 (2024.12)
Korean 493.5 KB
2025-03-24 00:00
Annual / Quarterly Financial Statement
[기재정정]연결감사보고서 (2024.12)
Korean 504.6 KB
2025-03-24 00:00
Registration Form
증권신고서(지분증권)
Korean 3.0 MB
2025-03-18 00:00
Annual / Quarterly Financial Statement
감사보고서 (2024.12)
Korean 488.6 KB
2025-03-18 00:00
Audit Report / Information
연결감사보고서 (2024.12)
Korean 499.7 KB

Automate Your Workflow. Get a real-time feed of all BIOBIJOU Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BIOBIJOU Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BIOBIJOU Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP
ARROWHEAD PHARMACEUTICALS, INC. Logo
Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.
United States of America
ARWR
ARS Pharmaceuticals, Inc. Logo
Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.
United States of America
SPRY

Talk to a Data Expert

Have a question? We'll get back to you promptly.